Characteristics of the patients and regimens
| Subject . | Age, m . | Sex . | Weight, kg . | Length, cm . | Conditioning regimen . | Total nucleated cell dose, × 108 cells per kg . |
|---|---|---|---|---|---|---|
| Patient no. | ||||||
| 1 | 13 | F | 5.0 | 54.5 | busulfan (1 mg/kg × 16 doses) | 5.7 |
| Ara C (2 g/m2 × 6 doses) | ||||||
| cyclo (45 mg/kg × 2 doses) | ||||||
| 2 | 13 | M | 5.0 | 56.0 | busulfan (40 mg/m2 × 8 doses) | 6.2 |
| cyclo (60 mg/kg × 2 doses) | ||||||
| TBI (180 cGy × 5 doses) | ||||||
| 3 | 17 | M | 6.7 | 54.0 | busulfan (1 mg/kg × 16 doses) | 5.5 |
| cyclo (50 mg/kg × 4 doses) | ||||||
| Control no. | ||||||
| 1 | 13 | M | 7.3 | 63.0 | ||
| 2 | 13 | F | 7.1 | 66.0 |
| Subject . | Age, m . | Sex . | Weight, kg . | Length, cm . | Conditioning regimen . | Total nucleated cell dose, × 108 cells per kg . |
|---|---|---|---|---|---|---|
| Patient no. | ||||||
| 1 | 13 | F | 5.0 | 54.5 | busulfan (1 mg/kg × 16 doses) | 5.7 |
| Ara C (2 g/m2 × 6 doses) | ||||||
| cyclo (45 mg/kg × 2 doses) | ||||||
| 2 | 13 | M | 5.0 | 56.0 | busulfan (40 mg/m2 × 8 doses) | 6.2 |
| cyclo (60 mg/kg × 2 doses) | ||||||
| TBI (180 cGy × 5 doses) | ||||||
| 3 | 17 | M | 6.7 | 54.0 | busulfan (1 mg/kg × 16 doses) | 5.5 |
| cyclo (50 mg/kg × 4 doses) | ||||||
| Control no. | ||||||
| 1 | 13 | M | 7.3 | 63.0 | ||
| 2 | 13 | F | 7.1 | 66.0 |
Total nucleated cell dose includes cells from unmanipulated bone marrow (per kg recipient weight) that were transplanted. All patients received cyclosporine as prophylaxis against GVHD. Data for controls are presented at 13 months of age to facilitate comparison with patients. Ara C indicates cytarabine; cyclo, cyclophosphamide; and TBI, total body irradiation (added because sibling donor was a HLA-DRB1 mismatch).